ÂÜÀòÂÒÂ×

Gary Fanger has over 20 years of experience in the biotechnology industry developing novel therapeutics, establishing drug development alliances, and leading M&A activities. He serves as a director on the boards of Virtici and OncoImmune. In his previous role as Senior Vice President & Chief Operating Officer at Amplimmune, Dr. Fanger helped to lead the $500 million acquisition by Medimmune/AstraZeneca in 2013. Prior to joining Amplimmune, Dr. Fanger was Vice President of Business Development at MacroGenics where he directed partnering activities that included establishing MacroGenics’ strategic alliance with Eli Lilly & Company. Before MacroGenics, Dr. Fanger was responsible for a diverse array of corporate functions at Corixa Corporation, including heading up business development activities, establishing and directing the therapeutic antibody development program, and managing numerous pharma strategic alliances. Dr. Fanger has co-authored over 45 articles, book chapters, and reviews in peer-reviewed journals in the areas of molecular biology, cell biology, and drug development research. He has also been awarded 35 patents. Dr. Fanger received his MBA from Seattle University, PhD in Molecular and Cellular Biology from Dartmouth Medical School, and his BS in Chemistry from Denison University.